54 participants
Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-07-31
- Start Date:
- 2019-12-14
- Completion:
- 2023-10-30
Conditions
- Advanced Malignant Solid Neoplasm
- Metastatic Malignant Solid Neoplasm
- NF1 Mutation Positive Malignant Peripheral Nerve Sheath Tumor
- Unresectable Malignant Solid Neoplasm
Interventions
- PROCEDURE
- OTHER
- DRUG